Gus Khursigara

Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT.

Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA.